Per 25 mcg/250 mcg/actuation MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 250 mcg
Indications/Uses
Regular treatment of asthma, where use of a combination product (long-acting β2 agonist & inhaled corticosteroid) is appropriate. Patients not adequately controlled w/ inhaled corticosteroids & as needed inhaled short acting β2 agonist; already adequately controlled on both inhaled corticosteroid & long-acting β2 agonist.
Do not use to treat acute asthma symptoms for which fast & short-acting bronchodilator is required. Do not stop treatment abruptly. Patients w/ active or quiescent pulmonary TB & severe thyrotoxicosis. Pregnancy & lactation. May reduce growth velocity in childn.
R03AK06 - salmeterol and fluticasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Sign Out
